越南巴宁treatment-naïve慢性乙型肝炎患者的乙型肝炎病毒基因型和抗病毒药物耐药突变:一项横断面研究

IF 3.4 Q2 INFECTIOUS DISEASES
Therapeutic Advances in Infectious Disease Pub Date : 2025-06-14 eCollection Date: 2025-01-01 DOI:10.1177/20499361251344784
Minh-Cong Hoang, Hong-Quan Duong, Van-Duyet Le, Thi-Thuy-Nga Nguyen, Van-Lang Ngo, The-Hung Dang
{"title":"越南巴宁treatment-naïve慢性乙型肝炎患者的乙型肝炎病毒基因型和抗病毒药物耐药突变:一项横断面研究","authors":"Minh-Cong Hoang, Hong-Quan Duong, Van-Duyet Le, Thi-Thuy-Nga Nguyen, Van-Lang Ngo, The-Hung Dang","doi":"10.1177/20499361251344784","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vietnam has one of the highest hepatitis B virus (HBV) infection rates, with approximately 8 million people affected. Although antiviral drug resistance mutations have been reported in treatment-naïve patients with chronic hepatitis B, there is limited data on primary drug resistance mutations in circulating genotypes within this population.</p><p><strong>Objectives: </strong>This study aimed to investigate primary antiviral drug resistance mutations and common HBV genotypes in treatment-naïve patients with chronic hepatitis B, particularly in cases without well-characterized resistance profiles.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Methods: </strong>We analyzed HBV genotypes and antiviral drug resistance mutations in 113 treatment-naïve patients with chronic hepatitis B in the Yenphong Medical Center, Bacninh Vietnam. The reverse transcriptase (RT) region of the HBV polymerase genes was sequenced to detect mutations.</p><p><strong>Results: </strong>Genotypes B, C, and G were identified in 85.0% (96/133), 14.1% (16/133), and 0.9% (1/133) of treatment-naïve patients with chronic hepatitis B, respectively. Mutations in the RT region associated with antiviral drug resistance were detected in 32.7% (37/113) of patients. In addition, the most frequent resistance mutations were rtV207M (89.2%, 33/37), followed by A194T, L180M + M204V, V173L + M204I + L80I, and A181T + V207M + A181T, each observed in 2.7% (1/37). Notably, no significant associations were found between resistance mutations and HBV genotype, gender, age, hepatitis B e-antigen status, baseline HBV DNA levels, or level of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase.</p><p><strong>Conclusion: </strong>This study highlights the presence of primary resistance mutations in treatment-naïve patients and underscores the importance of genotypic screening prior to initiating therapy. These findings may inform treatment strategies and help reduce the risk of treatment failure, liver cirrhosis, and hepatocellular carcinoma.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251344784"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171249/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-naïve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study.\",\"authors\":\"Minh-Cong Hoang, Hong-Quan Duong, Van-Duyet Le, Thi-Thuy-Nga Nguyen, Van-Lang Ngo, The-Hung Dang\",\"doi\":\"10.1177/20499361251344784\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Vietnam has one of the highest hepatitis B virus (HBV) infection rates, with approximately 8 million people affected. Although antiviral drug resistance mutations have been reported in treatment-naïve patients with chronic hepatitis B, there is limited data on primary drug resistance mutations in circulating genotypes within this population.</p><p><strong>Objectives: </strong>This study aimed to investigate primary antiviral drug resistance mutations and common HBV genotypes in treatment-naïve patients with chronic hepatitis B, particularly in cases without well-characterized resistance profiles.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Methods: </strong>We analyzed HBV genotypes and antiviral drug resistance mutations in 113 treatment-naïve patients with chronic hepatitis B in the Yenphong Medical Center, Bacninh Vietnam. The reverse transcriptase (RT) region of the HBV polymerase genes was sequenced to detect mutations.</p><p><strong>Results: </strong>Genotypes B, C, and G were identified in 85.0% (96/133), 14.1% (16/133), and 0.9% (1/133) of treatment-naïve patients with chronic hepatitis B, respectively. Mutations in the RT region associated with antiviral drug resistance were detected in 32.7% (37/113) of patients. In addition, the most frequent resistance mutations were rtV207M (89.2%, 33/37), followed by A194T, L180M + M204V, V173L + M204I + L80I, and A181T + V207M + A181T, each observed in 2.7% (1/37). Notably, no significant associations were found between resistance mutations and HBV genotype, gender, age, hepatitis B e-antigen status, baseline HBV DNA levels, or level of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase.</p><p><strong>Conclusion: </strong>This study highlights the presence of primary resistance mutations in treatment-naïve patients and underscores the importance of genotypic screening prior to initiating therapy. These findings may inform treatment strategies and help reduce the risk of treatment failure, liver cirrhosis, and hepatocellular carcinoma.</p>\",\"PeriodicalId\":46154,\"journal\":{\"name\":\"Therapeutic Advances in Infectious Disease\",\"volume\":\"12 \",\"pages\":\"20499361251344784\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171249/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Infectious Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20499361251344784\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361251344784","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:越南是乙型肝炎病毒(HBV)感染率最高的国家之一,约有800万人受到影响。虽然在treatment-naïve慢性乙型肝炎患者中有抗病毒药物耐药突变的报道,但在该人群中循环基因型的主要耐药突变的数据有限。目的:本研究旨在调查treatment-naïve慢性乙型肝炎患者的原发性抗病毒药物耐药突变和常见HBV基因型,特别是在没有明确耐药谱的病例中。设计:横断面研究。方法:我们分析了113例treatment-naïve慢性乙型肝炎患者的HBV基因型和抗病毒药物耐药突变。对HBV聚合酶基因的逆转录酶(RT)区域进行测序以检测突变。结果:在treatment-naïve慢性乙型肝炎患者中,分别有85.0%(96/133)、14.1%(16/133)和0.9%(1/133)检测到B、C和G基因型。32.7%(37/113)的患者检测到与抗病毒药物耐药相关的RT区突变。耐药突变以rtV207M最多,占89.2%(33/37),其次为A194T、L180M + M204V、V173L + M204I + L80I和A181T + V207M + A181T,各占2.7%(1/37)。值得注意的是,耐药性突变与HBV基因型、性别、年龄、乙型肝炎e抗原状态、基线HBV DNA水平或丙氨酸转氨酶、天冬氨酸转氨酶、γ -谷氨酰转移酶水平之间没有显著关联。结论:这项研究强调了treatment-naïve患者中原发性耐药突变的存在,并强调了在开始治疗前进行基因型筛查的重要性。这些发现可能为治疗策略提供信息,并有助于降低治疗失败、肝硬化和肝细胞癌的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-naïve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study.

Background: Vietnam has one of the highest hepatitis B virus (HBV) infection rates, with approximately 8 million people affected. Although antiviral drug resistance mutations have been reported in treatment-naïve patients with chronic hepatitis B, there is limited data on primary drug resistance mutations in circulating genotypes within this population.

Objectives: This study aimed to investigate primary antiviral drug resistance mutations and common HBV genotypes in treatment-naïve patients with chronic hepatitis B, particularly in cases without well-characterized resistance profiles.

Design: A cross-sectional study.

Methods: We analyzed HBV genotypes and antiviral drug resistance mutations in 113 treatment-naïve patients with chronic hepatitis B in the Yenphong Medical Center, Bacninh Vietnam. The reverse transcriptase (RT) region of the HBV polymerase genes was sequenced to detect mutations.

Results: Genotypes B, C, and G were identified in 85.0% (96/133), 14.1% (16/133), and 0.9% (1/133) of treatment-naïve patients with chronic hepatitis B, respectively. Mutations in the RT region associated with antiviral drug resistance were detected in 32.7% (37/113) of patients. In addition, the most frequent resistance mutations were rtV207M (89.2%, 33/37), followed by A194T, L180M + M204V, V173L + M204I + L80I, and A181T + V207M + A181T, each observed in 2.7% (1/37). Notably, no significant associations were found between resistance mutations and HBV genotype, gender, age, hepatitis B e-antigen status, baseline HBV DNA levels, or level of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase.

Conclusion: This study highlights the presence of primary resistance mutations in treatment-naïve patients and underscores the importance of genotypic screening prior to initiating therapy. These findings may inform treatment strategies and help reduce the risk of treatment failure, liver cirrhosis, and hepatocellular carcinoma.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
8.80%
发文量
64
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信